

# UnitedHealthcare Community Plan Medical Policy Update Bulletin: July 2023

Access a policy listed below for complete details on the latest updates. A comprehensive summary of changes is provided at the bottom of every policy document for your reference. To view a detailed version of this bulletin, click here.

# **Take Note**

### Quarterly CPT° and HCPCS Code Updates

Effective **Jul. 1, 2023**, all applicable Medical Policies and Medical Benefit Drug Policies have been updated to reflect the quarterly Current Procedural Terminology (CPT<sup>®</sup>) and Healthcare Common Procedure Coding System (HCPCS) code additions and deletions. Refer to the following sources for information on the code updates:

- American Medical Association. Current Procedural Terminology: CPT<sup>®</sup>
- Centers for Medicare & Medicaid Services. Healthcare Common Procedure Coding System: HCPCS Quarterly Update

For the list of impacted policies and corresponding details, click here.

# **Medical Policy Updates**

Policy Title	Status	Effective Date
Chelation Therapy for Non-Overload Conditions	Updated	Sep. 1, 2023
Chelation Therapy for Non-Overload Conditions (for New Jersey Only)	Updated	Sep. 1, 2023
Continuous Glucose Monitoring and Insulin Delivery for Managing Diabetes (for Nebraska Only)	Revised	Sep. 1, 2023
Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Nebraska Only)	Revised	Jul. 1, 2023
Enteral Nutrition (Oral and Tube Feeding) (for Nebraska Only)	Updated	Sep. 1, 2023
Gynecomastia Surgery	Updated	Jul. 1, 2023
Gynecomastia Surgery (for Florida Only)	Updated	Jul. 1, 2023
Gynecomastia Surgery (for New Jersey Only)	Updated	Jul. 1, 2023
Home Health, Skilled, and Custodial Care Services	Revised	Sep. 1, 2023
Home Health, Skilled, and Custodial Care Services (for Nebraska Only)	Updated	Sep. 1, 2023
Home Health, Skilled, and Custodial Care Services (for New Jersey Only)	Updated	Sep. 1, 2023
Intrauterine Fetal Surgery	Updated	Jul. 1, 2023
Lower Extremity Endovascular Procedures	Revised	Sep. 1, 2023
Lower Extremity Endovascular Procedures (for New Jersey Only)	Revised	Sep. 1, 2023
Manipulative Therapy	Revised	Sep. 1, 2023
Manipulative Therapy (for Nebraska Only)	Revised	Sep. 1, 2023
Manipulative Therapy (for New Jersey Only)	Revised	Sep. 1, 2023
Mobility Devices, Options and Accessories (for Nebraska Only)	Revised	Sep. 1, 2023
Obstructive and Central Sleep Apnea Treatment (for Nebraska Only)	Updated	Jul. 1, 2023
Panniculectomy and Body Contouring Procedures (for Nebraska Only)	Revised	Sep. 1, 2023

Policy Title	Status	Effective Date
Patient Lifts (for Nebraska Only)	Revised	Sep. 1, 2023
Pectus Deformity Repair	Updated	Sep. 1, 2023
Pectus Deformity Repair (for New Jersey Only)	Updated	Sep. 1, 2023
Rhinoplasty and Other Nasal Procedures (for Nebraska Only)	Revised	Sep. 1, 2023
Rhinoplasty and Other Nasal Procedures (for New Jersey Only)	Revised	Aug. 1, 2023

# Medical Benefit Drug Policy Updates

Policy Title	Status	Effective Date
17-Alpha-Hydroxyprogesterone Caproate (Makena® and 17P)	Revised	Aug. 1, 2023
Actemra® (Tocilizumab) Injection for Intravenous Infusion	Updated	Jul. 1, 2023
Antiemetics for Oncology	Updated	Aug. 1, 2023
Briumvi <sup>®</sup> (Ublituximab-Xiiy)	New	Aug. 1, 2023
Denied Drug Codes - Pharmacy Benefit Drugs (for Arizona Only)	Revised	Jul. 1, 2023
Denosumab (Prolia® & Xgeva®)	Updated	Jul. 1, 2023
Entyvio® (Vedolizumab)	Updated	Jul. 1, 2023
Evenity® (Romosozumab-Aqqg)	Updated	Jul. 1, 2023
Evkeeza® (Evinacumab-Dgnb)	Revised	Jul. 1, 2023
Gonadotropin Releasing Hormone Analogs	Revised	Aug. 1, 2023
Infliximab (Avsola®, Inflectra®, Remicade®, & Renflexis®)	Updated	Jul. 1, 2023
Ketalar® (Ketamine) and Spravato® (Esketamine)	Updated	Jul. 1, 2023
Lemtrada® (Alemtuzumab)	Updated	Jul. 1, 2023
Medical Therapies for Enzyme Deficiencies	Revised	Aug. 1, 2023
Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease	Updated	Jul. 1, 2023
Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease	Updated	Aug. 1, 2023
Ocrevus® (Ocrelizumab)	Updated	Jul. 1, 2023
Ocrevus® (Ocrelizumab)	Revised	Aug. 1, 2023
Orencia® (Abatacept) Injection for Intravenous Infusion	Updated	Jul. 1, 2023
Qalsody <sup>™</sup> (Tofersen)	New	Aug. 1, 2023
Reblozyl® (Luspatercept-Aamt)	Updated	Jul. 1, 2023
Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®)	Updated	Jul. 1, 2023
Rituximab (Riabni <sup>™</sup> , Rituxan <sup>®</sup> , Ruxience <sup>®</sup> , & Truxima <sup>®</sup> )	Updated	Aug. 1, 2023
Simponi Aria® (Golimumab) Injection for Intravenous Infusion	Updated	Jul. 1, 2023
Skyrizi® (Risankizumab-Rzaa)	Updated	Jul. 1, 2023
Stelara® (Ustekinumab)	Updated	Jul. 1, 2023
Syfovre <sup>™</sup> (Pegcetacoplan Injection)	Revised	Aug. 1, 2023
Tepezza® (Teprotumumab-Trbw)	Revised	Aug. 1, 2023
Tezspire® (Tezepelumab-Ekko)	Updated	Jul. 1, 2023
Tysabri® (Natalizumab)	Updated	Jul. 1, 2023
Vyepti® (Eptinezumab-Jjmr)	Updated	Jul. 1, 2023
Zolgensma® (Onasemnogene Abeparvovec-Xioi)	Updated	Jul. 1, 2023

# **General Information**

The inclusion of a health service (e.g., test, drug, device or procedure) in this bulletin indicates only that UnitedHealthcare is adopting a new policy and/or updated, revised, replaced or retired an existing policy; it does not imply that UnitedHealthcare provides coverage for the health service. Note that most benefit plan documents exclude from benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health care professionals may not seek or collect payment from a member for services not covered by the applicable benefit plan unless first obtaining the member's written consent, acknowledging that the service is not covered by the benefit plan and that they will be billed directly for the service.

Note: The absence of a policy does not automatically indicate or imply coverage. As always, coverage for a health service must be determined in accordance with the member's benefit plan and any applicable federal or state regulatory requirements. Additionally, UnitedHealthcare reserves the right to review the clinical evidence supporting the safety and effectiveness of a medical technology prior to rendering a coverage determination.

UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Medical Policy Update Bulletin was developed to share important information regarding UnitedHealthcare Medical Policy, Medical Benefit Drug Policy, Coverage Determination Guideline, and Utilization Review Guideline updates. When information in this bulletin conflicts with applicable state and/or federal law, UnitedHealthcare follows such applicable federal and/or state law.

## **Policy Update Classifications**

#### New

New clinical coverage criteria have been adopted for a health service (e.g., test, drug, device or procedure)

#### Updated

An existing policy has been reviewed and changes have not been made to the clinical coverage criteria; however, items such as the clinical evidence, FDA information, and/or list(s) of applicable codes may have been updated

#### Revised

An existing policy has been reviewed and revisions have been made to the clinical coverage criteria

#### Replaced

An existing policy has been replaced with a new or different policy

#### Retired

The health service(s) addressed in the policy are no longer being managed or are considered to be proven/medically necessary and are therefore not excluded as unproven/not medically necessary services, unless coverage guidelines or criteria are otherwise documented in another policy



The complete library of UnitedHealthcare Community Plan Medical Policies, Medical Benefit Drug Policies, Coverage Determination Guidelines, and Utilization Review Guidelines is available at **UHCprovider.com** > Policies and Protocols > Community Plan Policies > Medical & Drug Policies and Coverage Determination Guidelines for Community Plan.